Zhang Jingdan, Yang Xiangling, Wei Lili, Tan Huiliu, Chen Junxiong, Li Weiqian, Chan Kawo, Su Yixi, Zhao Lu, Hu Suhua, Zhong Shuoxian, Xiao Yanhong, Liu Huanliang
Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
J Cancer. 2020 Sep 17;11(22):6491-6496. doi: 10.7150/jca.45204. eCollection 2020.
The incidence of colorectal cancer (CRC) ranks third among all cancers in China and improvements in screening for CRC have an important impact on prevention and control of the disease. Paraoxonase 1 (PON1) is a calcium ion-dependent hydrolase that is widely distributed in tissue. Its diagnostic value in colorectal cancer has been reported, but the diagnostic value of combining PON1 with carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 12-5 (CA12-5) in colorectal cancer has not been evaluated. Experiments were carried out in a total of 284 CRC patients and 90 healthy controls. The primary cohort was randomly divided into training and validation sets. The levels of PON1 in plasma of CRC patients were significantly lower than that in the healthy controls ( < 0.001). It showed excellent diagnostic value with the AUC reaching 0.750 for the training set and 0.742 for the validation set. Furthermore, combining PON1 with CEA, CA12-5, CA19-9 could better classify CRC patients (AUC rising from 0.821, 0.716, 0.712 to 0.875, 0.817 and 0.814, respectively, in the training set, from 0.818, 0.581, 0.593 to 0.854, 0.770, and 0.772 in the validation set). In conclusion, PON1 can serve as a diagnostic biomarker for CRC and raise the sensitivity and specificity when incorporated with traditional tumor biomarkers.
在中国，结直肠癌（CRC）的发病率在所有癌症中排名第三，改善CRC筛查对该疾病的预防和控制具有重要影响。对氧磷酶1（PON1）是一种钙离子依赖性水解酶，广泛分布于组织中。其在结直肠癌中的诊断价值已有报道，但PON1与癌胚抗原（CEA）、糖类抗原19-9（CA19-9）、糖类抗原12-5（CA12-5）联合在结直肠癌中的诊断价值尚未评估。共对284例CRC患者和90例健康对照进行了实验。将主要队列随机分为训练集和验证集。CRC患者血浆中PON1水平显著低于健康对照（<0.001）。其显示出优异的诊断价值，训练集的AUC达到0.750，验证集的AUC达到0.742。此外，将PON1与CEA、CA12-5、CA19-9联合可更好地对CRC患者进行分类（训练集中AUC分别从0.821、0.716、0.712升至0.875、0.817和0.814，验证集中从0.818、0.581、0.593升至0.854、0.770和0.772）。总之，PON1可作为CRC的诊断生物标志物，与传统肿瘤生物标志物联合使用时可提高敏感性和特异性。
